Navigation Links
Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
Date:11/8/2012

LANCASTER, Pa. and ROCKVILLE, Md., Nov. 8, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax™ vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan. JRC-LAMP-vax vaccine is a plasmid-based DNA vaccine that will be studied for its safety and immunological activity in the treatment of patients with rhino-conjunctivitis symptoms caused by allergic reaction to Japanese red cedar pollen. Enrollees in the study each received the first of a four (4) dosing vaccine regimen and were followed for 3 hours; no adverse events were observed in these patients.

ITI intends to complete enrollment in the study in November, the dosing of all patients early in 2013, and to follow up with a Phase II trial beginning in 2013. ITI's CEO, Dr. William Hearl, commented, "The successful initiation of this clinical study marks a significant milestone in the history of Immunomic Therapeutics. We are both pleased and excited that we are now a clinical - stage company. We are looking forward to completing the study and advancing the development of this important vaccine and other LAMP-vax™ vaccines."

Dr. Bruce F. Mackler, Vice President of Regulatory and Clinical Affairs, Immunomic Therapeutics, Inc., indicated that "ITI is committed to the rapid expansion of its clinical program based on the outcome of this first Japanese red cedar vaccine. We plan to move rapidly into the clinical testing of the multivalent vaccine in naturally sensitive Japanese ex-patriates as well as U.S. subjects with sensitivity to mountain cedar. This stu
'/>"/>

SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
2. Echo Therapeutics Announces Third Quarter 2012 Financial Results
3. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
4. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
5. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Novelos Therapeutics Closes $2 Million Private Placement
7. US Allows Two Key Patents for Silence Therapeutics
8. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
9. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
10. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
11. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... 2014  NuView Life Sciences, Inc. (NuView) announced ... agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to ... biomarker to detect cancers of the breast and ... diagnostic-imaging applications. NuView retains all rights for the ... urine screen applications. Under the terms ...
(Date:9/17/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ... $4 million milestone payment from Achaogen, Inc. (NASDAQ: ... of a Phase 3 study of plazomicin in ... infections.  The Phase 3 study is designed as ... safety of plazomicin compared to colistin in patients ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... Belt Technologies, Inc., a Pittsburgh based medical device company ... use in orthopaedic and neurosurgery procedures, has closed on ... financing. The round was led by private investors ... Works (Pittsburgh) and consisted of both new investments and ...
... Sept. 30 Law firm Clifford Chance, as international counsel, ... with Wyeth under China,s Anti-Monopoly Law. The clearance was issued ... , Competition approval from the Chinese authorities was one of ... The EU has already approved the deal; decisions are awaited ...
Cached Medicine Technology:Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... multi-center U.S. registry on the efficacy of carotid stenting ... are at high risk for standard surgical therapy.// ... CAPTURE (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare ... Cardiology’s 55th Annual Session in Atlanta. The multi-center study ...
... with a friend will be more beneficial to health than ... Elizabeth Gould at Harvard University compared the costs and benefits ... and found that contrary to accepted wisdom, jogging was not ... Daily Mail. ,The researchers carried out series of ...
... Hopkins University School of Medicine said that genetic material in ... // , The researchers feel that it very ... of mutated human genes. ,Jef Boeke described about ... the yeast cells which is necessary for the stability of ...
... spells doom for global economic growth. According to bank economist ... a dent of two to six percentage out of global ... rate reductions and older populations, which will lead to continued ... Burns, has been getting Bay Street and investors to gear ...
... at the end of the tunnel. Those infected with human ... workplaces. // Employers will have to face legal charges if ... ,HIV causes acquired immune deficiency syndrome. The ministry of ... of HIV/AIDS, which will seek to protect the rights of ...
... and 170 suspected cases of meningococcimia or meningitis in New ... who are taking strict measures to check the spread of ... sure that family members and neighbors of infected persons are ... also distributing leaflets to educate people about the symptoms of ...
Cached Medicine News:Health News:Carotid Stenting Can Help Patients With Silent Disease 2Health News:Carotid Stenting Can Help Patients With Silent Disease 3Health News:Carotid Stenting Can Help Patients With Silent Disease 4
... anesthesia workstation provides an intelligent approach ... to provide true clinical benefits to ... the art computer technology integrates hemodynamic ... color touchscreen display panel. The open ...
... Cost effective technology in anesthesia., ,Whether ... manual ventilation, the operating theater or as ... integrated monitoring, the Aliseo product family allows ... ,With three product models, you have ...
... in facilities where space is a premium ... gas delivery technologies with an ergonomic and ... functionality of the Draeger Infinity patient monitoring ... workplace environment that is a sound investment ...
... A new level of excellence and ... advanced anesthesia delivery system with basic ventilation ... industry leading excellence of the Aestiva/5 Anesthesia ... compact design - it features a configurable ...
Medicine Products: